2-Deoxy-D-glucose: Advanced Insights into Immunometabolic Targeting and Tumor Microenvironment Modulation

Introduction

2-Deoxy-D-glucose (2-DG), a potent glycolysis inhibitor, has emerged as a cornerstone tool in metabolic pathway research, cancer therapy development, and antiviral studies. Unlike conventional metabolic inhibitors, 2-DG uniquely disrupts ATP synthesis and induces metabolic oxidative stress, influencing not only cancer cell viability but also the immunometabolic landscape of the tumor microenvironment. Building on existing literature, this article provides a differentiated, in-depth analysis of 2-DG’s advanced applications, focusing on its interplay with immune cell reprogramming and recent breakthroughs in metabolic checkpoint modulation. We integrate findings from the seminal study by Xiao et al. (2024, Immunity) to highlight new frontiers in tumor immunometabolism that position 2-DG at the nexus of cancer and immune research.

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

Glycolysis Inhibition and ATP Synthesis Disruption

2-Deoxy-D-glucose is a glucose analog structurally similar to D-glucose but with a key modification at the 2-position, rendering it non-metabolizable beyond the initial phosphorylation step by hexokinase. This competitive inhibition blocks glycolytic flux, resulting in the accumulation of 2-DG-phosphate and depletion of downstream glycolytic intermediates. The direct consequence is profound ATP synthesis disruption, leading to altered cellular energy homeostasis and the induction of metabolic oxidative stress. As a 2-DG glycolysis inhibitor, 2-DG is widely employed to interrogate the metabolic dependencies of rapidly proliferating cells, including cancer cells and virally infected cells.

Impact on Metabolic Pathways and Signal Transduction

Beyond glycolysis, 2-DG’s effects ripple through multiple metabolic and signaling networks. It perturbs the pentose phosphate pathway, impairs N-linked glycosylation, and can modulate the PI3K/Akt/mTOR signaling pathway—a central node in cellular growth and survival. This multifaceted mechanism positions 2-DG as a versatile metabolic pathway research tool, enabling the dissection of complex metabolic crosstalk in various biological systems.

Advanced Applications in Tumor Microenvironment Modulation

Targeting KIT-positive Gastrointestinal Stromal Tumors and Beyond

2-DG has demonstrated cytotoxicity against KIT-positive gastrointestinal stromal tumor (GIST) cell lines, with reported IC₅₀ values of 0.5 μM (GIST882) and 2.5 μM (GIST430). This selectivity is attributed to the heightened glycolytic dependence of KIT-mutant cells. Notably, 2-DG augments the efficacy of chemotherapeutic agents such as Adriamycin and Paclitaxel, leading to significantly slower tumor growth in nude mouse xenograft models of human osteosarcoma and non-small cell lung cancer. These findings support the rationale for incorporating 2-DG into combination regimens targeting non-small cell lung cancer metabolism and other glycolysis-addicted malignancies.

Immunometabolic Reprogramming: Insights from 25-Hydroxycholesterol Research

Recent advances in immunometabolic research have revealed that metabolic modulation extends beyond intrinsic tumor cell pathways. The study by Xiao et al. (2024) uncovered how the oxysterol 25-hydroxycholesterol (25HC) accumulates within tumor-associated macrophages (TAMs) and activates lysosomal AMP-activated protein kinase (AMPKa) via the GPR155-mTORC1 axis. This activation reprograms TAMs towards an immunosuppressive phenotype, dampening anti-tumor immunity. Critically, targeting the CH25H-25HC axis not only reverts TAMs to a more inflammatory state but also enhances the efficacy of immune checkpoint blockade.

This mechanism underscores the potential for glycolysis inhibition in cancer research—via agents like 2-DG—to synergize with metabolic checkpoint targeting, reshape the tumor microenvironment, and improve therapeutic outcomes. By disrupting ATP production and metabolic support in both tumor and immune cells, 2-DG may potentiate the re-education of TAMs and the infiltration of cytotoxic T cells, thus converting 'cold' tumors into 'hot,' immune-responsive states.

Distinctive Perspective: Bridging Metabolic and Immune Modulation

While previous articles, such as "2-Deoxy-D-glucose: Unraveling Metabolic Checkpoints in Tumor Immunology", have highlighted 2-DG’s role as a glycolysis inhibitor and its influence on the tumor microenvironment, this article uniquely deepens the discussion by integrating new evidence from oxysterol–AMPK–STAT6 signaling. We focus on the crosstalk between metabolic inhibition and immunometabolic education of macrophages, providing a mechanistic bridge to recent immunotherapy advances.

Comparative Analysis with Alternative Metabolic Modulators

2-DG Versus Alternative Glycolytic Inhibitors

Alternative glycolytic inhibitors, such as lonidamine, 3-bromopyruvate, and dichloroacetate, have been evaluated for their anticancer potential. However, 2-DG’s unique ability to accumulate intracellularly as a non-metabolizable phosphate derivative allows for sustained glycolytic blockade and a pronounced induction of metabolic oxidative stress. Unlike agents targeting single enzymes, 2-DG’s competitive inhibition at the entry point of glycolysis ensures broader metabolic suppression and greater translational applicability in diverse cancer and virology models.

Synergy with Chemotherapeutics and Immunotherapies

2-DG enhances the cytotoxicity of chemotherapeutics by exacerbating energy stress and impairing DNA repair capacity in cancer cells. This synergy is especially pronounced in glycolysis-addicted tumors, such as KIT-positive GISTs and non-small cell lung cancers. Recent insights into immunometabolic checkpoints suggest that 2-DG may further potentiate the efficacy of immune checkpoint inhibitors by modulating the metabolic fitness of both tumor and immune cells. This dual targeting capability distinguishes 2-DG from agents with narrower mechanisms of action.

The article "2-Deoxy-D-glucose: Redefining Tumor Immunometabolism and Precision Therapy" provides a broad overview of 2-DG’s translational opportunities and acknowledges the relevance of metabolic checkpoints. In contrast, our discussion delves into the molecular interplay between glycolysis inhibition, oxysterol-induced AMPK activation, and immune cell polarization, synthesizing a new narrative for therapeutic innovation.

Expanding Applications: Antiviral Research and Metabolic Pathway Studies

Viral Replication Inhibition

Beyond oncology, 2-DG exerts potent antiviral effects by impairing viral protein translation during the early stages of infection. In vitro, 2-DG inhibits replication and gene expression of porcine epidemic diarrhea virus (PEDV) in Vero cells, underscoring its utility as a viral replication inhibition agent. This broad-spectrum antiviral activity stems from the dependency of many viruses on host glycolytic machinery for replication and assembly.

Protocol Optimization and Experimental Considerations

For metabolic pathway interrogation, typical experimental conditions for 2-DG include treatment concentrations of 5–10 mM for 24 hours. The compound demonstrates excellent solubility (≥105 mg/mL in water, ≥2.37 mg/mL in ethanol with warming and ultrasonic treatment, and ≥8.2 mg/mL in DMSO), allowing for flexibility in experimental design. Storage at -20°C is recommended, with caution against prolonged solution storage to preserve activity and reproducibility. For researchers seeking a reliable and pure source, 2-Deoxy-D-glucose (2-DG), SKU B1027 offers robust performance in both in vitro and in vivo studies.

For detailed protocol enhancements and troubleshooting, readers may also consult "2-Deoxy-D-glucose: Transforming Glycolysis Inhibition in Cancer and Virology", which complements our mechanistic focus by providing hands-on workflow guidance.

PI3K/Akt/mTOR Pathway and the Future of Immunometabolic Targeting

Integrating Glycolysis Inhibition with Signaling Pathway Modulation

The PI3K/Akt/mTOR axis orchestrates cellular metabolism, growth, and survival—processes frequently dysregulated in cancer. 2-DG disrupts this pathway both directly, by depleting ATP, and indirectly, by enhancing AMPK activity, which negatively regulates mTORC1. The recent elucidation of the GPR155-mTORC1-AMPKa-STAT6 signaling route by Xiao et al. provides a framework for understanding how metabolic interventions can rewire immune cell function within tumors. Thus, 2-DG, as a PI3K/Akt/mTOR signaling pathway modulator, represents a promising adjunct in strategies aimed at reversing immunosuppression and sensitizing tumors to immunotherapy.

Conclusion and Future Outlook

2-Deoxy-D-glucose stands at the intersection of metabolic and immunological research, offering unique leverage points for therapeutic intervention. By simultaneously disrupting glycolytic flux, inducing metabolic oxidative stress, and modulating key immunometabolic checkpoints, 2-DG provides a multi-layered approach to tackling cancer and viral diseases. The integration of recent mechanistic insights—such as those regarding 25-hydroxycholesterol–AMPK–STAT6 signaling—heralds a new era of rational, combination-based therapy design.

As the field advances, future research should aim to delineate the optimal integration of 2-DG with agents targeting the CH25H-25HC axis, immune checkpoint inhibitors, and traditional chemotherapeutics. For researchers and clinicians seeking to harness the full potential of 2-Deoxy-D-glucose (2-DG), a nuanced understanding of these interconnected pathways will be indispensable. To further explore precision metabolic control and translational strategies, see also "2-Deoxy-D-glucose: Unveiling Precision Metabolic Control in Tumor and Immune Cells", which complements our immunometabolic emphasis by focusing on experimental precision.

Ultimately, 2-DG’s multifaceted role as a 2 deoxyglucose, 2 deoxy d glucose, 2d glucose, 2 d glucose, 2 deoxy d glucose 2 dg serves as a catalyst for innovation across oncology and virology, with expanding frontiers in immunometabolic reprogramming and tumor microenvironment modulation.